Comparative Pharmacology
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus SERPIVITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYCLOTHIAZIDE AND DESERPIDINE versus SERPIVITE.
METHYCLOTHIAZIDE AND DESERPIDINE vs SERPIVITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
Selective serotonin reuptake inhibitor (SSRI); increases serotonin levels in the synaptic cleft by blocking reuptake via SERT inhibition.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
1.5 mg/kg IV every 12 hours; maximum single dose 120 mg.
None Documented
None Documented
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Terminal elimination half-life 12 hours; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min)
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Renal excretion unchanged 70%, biliary/fecal 25%, metabolic clearance 5%
Category C
Category C
Thiazide Diuretic and Antihypertensive
Antihypertensive